{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:59Z","timestamp":1707524579349},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"DOI":"10.7759\/cureus.22764","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T13:09:28Z","timestamp":1646226568000},"source":"Crossref","is-referenced-by-count":0,"title":["Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Precious O","family":"Idogun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeina","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy GK","year":"2013","unstructured":"Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013, 63:249-79. 10.3322\/caac.21184","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"FDA D.I.S.C.O. Burst edition. FDA approval of Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. (2021). Accessed: January 24, 2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-sarclisa-isatuxim...."},{"key":"ref3","unstructured":"SARCLISA\u00ae (isatuximab-irfc) | Official HCP Site [Internet]. (2022). Accessed. January 24, 2022: https:\/\/www.sarclisahcp.com\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/ refractory multiple myeloma: IKEMA phase III study design","volume":"16","author":"Moreau P","year":"2020","unstructured":"Moreau P, Dimopoulos M, Yong K, Mikhael J, Risse M, Asset G, Martin T. Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/ refractory multiple myeloma: IKEMA phase III study design. Future Oncol. 2020, 16:4347-4358. 10.1016\/S0140-6736(21)00592-4","journal-title":"Future Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.20.04149-X","article-title":"Monoclonal antibodies in multiple myeloma","volume":"63","author":"Vozella F","year":"2021","unstructured":"Vozella F, Fazio F, Lapietra G, Petrucci MT, Martinelli G, Cerchione C. Monoclonal antibodies in multiple myeloma. Panminerva Med. 2021, 63:21-7. 10.23736\/S0031-0808.20.04149-X","journal-title":"Panminerva Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: diagnosis, assessment, and management","volume":"14","author":"Vogel WH","year":"2010","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010, 14:E10-21. 10.1188\/10.CJON.E10-E21","journal-title":"Clin J Oncol Nurs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger L","year":"2015","unstructured":"Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015, 4:e39. 10.1038\/cti.2015.14","journal-title":"Clin Transl Immunology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95. 10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010063","article-title":"Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects","volume":"28","author":"Lassiter G","year":"2021","unstructured":"Lassiter G, Bergeron C, Guedry R, et al.. Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects. Curr Oncol. 2021, 28:640-60. 10.3390\/curroncol28010063","journal-title":"Curr Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-20-21","article-title":"Targeted cancer therapy and its ophthalmic side effects: a review","volume":"4","author":"Bindiganavile S","year":"2021","unstructured":"Bindiganavile S, Bhat N, Lee A, Gombos D, Al-Zubidi N. Targeted cancer therapy and its ophthalmic side effects: a review. J Immunother Precis Oncol. 2021, 4:6-15. 10.36401\/JIPO-20-21","journal-title":"J Immunother Precis Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton JS","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015, 31:589-604. 10.1089\/jop.2015.0064","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/87329-hemorrhagic-chemosis-associated-with-isatuximab-use-in-an-elderly-lady-with-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:29Z","timestamp":1707507569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/87329-hemorrhagic-chemosis-associated-with-isatuximab-use-in-an-elderly-lady-with-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.22764","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,2]]}}}